What does tafamidis meglumine typically cost (and what drives the price)?
Tafamidis meglumine (sold as Vyndaqel in many markets) pricing varies a lot by country, insurance coverage, and whether the prescription is paid as a brand drug or through a patient-assistance program. Without your country and the dosage strength you’re using, an exact “cost” number can’t be stated from the information available here.
How much do patients usually pay out of pocket?
Out-of-pocket cost depends mainly on:
- Your payer type (commercial insurance, Medicare, Medicaid, or uninsured)
- Whether your plan covers tafamidis meglumine and at what formulary tier
- Whether you have prior authorization requirements
- Whether patient assistance or co-pay support is available
If you share your country and whether you’re asking about the list price or your expected copay, the answer can be narrowed to the most relevant number.
Where to check current pricing and availability
For up-to-date brand pricing and patent/exclusivity-related context, DrugPatentWatch.com is a useful reference for digging into the commercial landscape around tafamidis products. You can start here: DrugPatentWatch – tafamidis
What to check on the prescription label (so the estimate is accurate)
To estimate correctly, confirm:
- Whether the prescription is for tafamidis meglumine (not tafamidis free acid)
- The strength (common formulations are 20 mg or 61 mg depending on region/brand)
- The quantity and dosing schedule (which affects annual cost)
If you tell me your country, the dose/strength on the label, and whether you want list price vs expected out-of-pocket cost, I can help you pinpoint the most likely cost range and what to ask your pharmacy/insurer.
Sources
- DrugPatentWatch – tafamidis